Also known as: AL001
Anlotinib (now INN catequentinib) is a multi-target tyrosine kinase inhibitor used in oncology. It is approved in China for selected advanced cancers including NSCLC after prior systemic chemotherapy and advanced soft-tissue sarcoma as second-line treatment. It is marketed under the trade name Focus V.
Alzamend Neuro reports pharmacodynamic data showing AL001 may have a distinct brain interaction profile compared to lithium carbonate, with potential tolerability advantages. The Phase II trial analysis suggests AL001 affects key brain metabolites differently while maintaining lithium's core mechanism of action. Further confirmatory studies are planned to validate these initial findings.
China's regulatory reforms since 2015 have streamlined clinical trial and drug approval processes, accelerating development of advanced therapies like CAR-T and bispecific antibodies. These changes have boosted investor confidence and created opportunities for global pharmaceutical partnerships with Chinese biotech companies that have innovative pipelines but lack international marketing capabilities.
The bipolar depression treatment pipeline includes over 10 therapies from 8+ companies, with recent Phase 3 trials initiated for azetukalner and multiple emerging drugs targeting novel pathways expected to launch by 2036.
Recent studies demonstrate PD-1 antibody combinations improve survival in natural killer/T-cell lymphoma and show activity in previously treated advanced non-small cell lung cancer, with manageable safety profiles across treatment settings.
DelveInsight releases three separate pipeline reports covering metastatic prostate cancer (80+ companies, 85+ drugs), iPSC-derived NK cells (12+ companies, 15+ drugs), and interstitial lung diseases (120+ companies, 120+ drugs), highlighting recent regulatory approvals, trial launches, and emerging therapies.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07540390 |
GAPP Induction and Concurrent Chemoradiotherapy for High-risk Locoregionally Advanced NPC. |
NOT_YET_RECRUITING | PHASE3 |
| NCT07538271 |
A Study of Benmelstobart, Anlotinib, Chemotherapy and Thoracic Radiotherapy for People With Extensive-stage Small Cell Lung Cancer |
NOT_YET_RECRUITING | PHASE2 |
| NCT07538258 |
Benmelstobart Plus Anlotinib, Chemotherapy and Thoracic Radiation for Limited-Stage Small Cell Lung Cancer |
NOT_YET_RECRUITING | PHASE2 |
| NCT07537777 |
Benmelstobart Plus Anlotinib Combined With SBRT for Patients With Hepatocellular Carcinoma Failing First-Line Targeted Therapy |
NOT_YET_RECRUITING | PHASE2 |
| NCT07470840 |
SBRT Plus Anlotinib and Bimepolizumab in Locally Advanced or Metastatic Renal Cell Carcinoma |
NOT_YET_RECRUITING | PHASE2 |
| NCT07443397 |
Anlotinib Plus Whole-Brain Radiotherapy for Brain Metastases in SCLC Patients. |
RECRUITING | PHASE3 |
| NCT07388875 |
Sacituzumab Tirumotecan Plus Anlotinib in Previously Treated ES-SCLC |
NOT_YET_RECRUITING | PHASE2 |
| NCT07376499 |
Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction |
NOT_YET_RECRUITING | PHASE2 |
| NCT07330544 |
A Phase II Clinical Study Evaluating Entinostat With or Without Anlotinib + Fulvestrant for the Treatment of Hormone Receptor (HR) -Positive, Human Epidermal Growth Factor Receptor-2 (HER-2) -Negative Advanced Breast Cancer That Relapsed or Progressed After Endocrine Therapy |
RECRUITING | PHASE2 |
| NCT07320963 |
Chidamide in Combination With Toripalimab and Anlotinib in Recurrent/Metastatic Nasopharyngeal Carcinoma. |
NOT_YET_RECRUITING | PHASE1/PHASE2 |
